Notes
Products included in Health Canada's review were: daclatasvir (Daklinza), sofosbuvir (Sovaldi), ledipasvir/sofosbuvir (Harvoni)sofosbuvir/velpatasvir (Epclusa), sofosbuvir/velpatasvir/voxilaprevir (Vosevi), elbasvir/grazoprevir (Zepatier), and glecaprevir/pibrentasvir (Maviret).
Reference
Health Canada. Summary Safety Review - Direct-acting antivirals (DAAs) - Health Canada. Internet Document : 17 Feb 2020. Available from: URL: https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00234
Rights and permissions
About this article
Cite this article
Possible risk of dysglycaemia with use of direct-acting antivirals. Reactions Weekly 1794, 2 (2020). https://doi.org/10.1007/s40278-020-75798-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-75798-0